AB Science

AB · Euronext Paris · France

Public Market Listing

ABEuronext Paris

Euronext Paris primary exchange listing

Live quotes, historical charts, and market capitalization for AB Science are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
5Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
KIT (c-Kit), also PDGFR and Lyn/Fyn kinasesSmall molecule
Alzheimer's DiseaseAsthmaAmyotrophic Lateral SclerosisCOVID-19
Phase 1/2
TubulinSmall molecule
Acute Myeloid Leukemia

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
MasitinibPhase 3Amyotrophic Lateral Sclerosis
Est. primary completion 2027-12 · NCT03127267 · CT.gov ↗
What to watch
2028 (2)
December 2028 (2)
MasitinibPhase 3Alzheimer Disease
Est. primary completion 2028-12 · NCT05564169 · CT.gov ↗
What to watch
MasitinibPhase 3Amyotrophic Lateral Sclerosis (ALS)
Est. primary completion 2028-12-31 · NCT07174492 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (1)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-H1$0.6M$10M$10M$5.3Mreport ↗

Annual history (1 year)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$1.3M$2.3M$11M$1.7Mreport ↗

AB Science reported FY2025 revenue of $1.27M (€1.174M), up 10% YoY, and R&D spend of $2.26M (€2.090M), with cash and equivalents of $11.01M (€10.2M) at year-end. The company recorded an operating loss of €3.8M excluding non-recurring items, down 38% YoY, and a net loss of €1.557M, down 80% YoY; structured data show a quarterly net burn of $1.69M, with an additional €3.2M raised in April 2026.

During the period, key clinical events included authorizations to start the confirmatory Phase 3 masitinib trial in ALS and a Phase 3 trial in metastatic prostate cancer, plus published subgroup data on masitinib in ALS showing survival and functional benefits. In acute myeloid leukaemia, AB8939 progressed through Phase 1/2 stages, with four consecutive responses reported in combination with venetoclax, and received EU orphan drug designation. The company also reached a final agreement with financial creditors to defer loan repayments, completed several capital raises, and announced a voluntary temporary suspension of European trial recruitment while prioritising Phase 3 masitinib in ALS and Phase 1 AB8939 in AML.